您的当前位置:首页 > 行业数据 > 全球首个FGFR4抑制剂联合IO在HCC的临床设计:依帕戈替尼联合阿替利珠单抗的临床二期试验方案
图片属性
图片格式:PNG 图片大小:971KB 图片尺寸:2317*1171
同报告图片
 / 4
全球首个FGFR4抑制剂联合IO在HCC的临床设计:依帕戈替尼联合阿替利珠单抗的临床二期试验方案_第1页
PHxiZWdpbl9vZl9ib3h8PnwgUGFydCB8IERvc2UgUmVnaW1lbiAgICAgICB8IFNhbXBsZSBTaXplIChOKSB8CnwtLS0tLS18LS0tLS0tLS0tLS0tLS0tLS0tLS18LS0tLS0tLS0tLS0tLS0tLS18CnwgQSAgICB8IDE4MG1nIFFEICAgICAgICAgICB8IDYgICAgICAgICAgICAgICB8CnwgQSAgICB8IDMyMG1nIFFEICAgICAgICAgICB8IDYgICAgICAgICAgICAgICB8CnwgQSAgICB8IDE2MG1nIEJJRCAgICAgICAgICB8IDggICAgICAgICAgICAgICB8CnwgQSAgICB8IDIyMG1nIEJJRCAgICAgICAgICB8IDMzICAgICAgICAgICAgICB8CgrotYTmlpnmnaXmupDvvJrlhazlj7hQUFQ8fGVuZF9vZl9ib3h8Pg==
全球首个FGFR4抑制剂联合IO在HCC的临床设计:依帕戈替尼联合阿替利珠单抗的临床二期试验方案_第2页
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
全球首个FGFR4抑制剂联合IO在HCC的临床设计:依帕戈替尼联合阿替利珠单抗的临床二期试验方案_第3页
全球首个FGFR4抑制剂联合IO在HCC的临床设计:依帕戈替尼联合阿替利珠单抗的临床二期试验方案_第4页
fCDpobnnm64gICAgICAgICAgICAgICAgfCDkuK3lm70gICAgICAgICAgfCDnvo7lm70gICAgICAgICAgfCDkuK3nvo7lkIjorqEgICAgICAgIHwKfC0tLS0tLS0tLS0tLS0tLS0tLS0tLXwtLS0tLS0tLS0tLS0tLS18LS0tLS0tLS0tLS0tLS0tfC0tLS0tLS0tLS0tLS0tLS0tfAp8IOW5tOWPkeeXheeOhyAgICAgICAgICAgIHwgfjYwLDAwMCAgICAgICB8IH4xNCwwMDAgICAgICAgfCDigJQgICAgICAgICAgICAgICB8Cnwg5ZWG5Lia5r2c5Yqb77yIVVMk77yJICAgICB8IH5VUyQ2NTBtICAgICAgfCB+VVMkODUwbSAgICAgIHwgflVTJDEuNWJuICAgICAgIHwKCui1hOaWmeadpea6kO+8muWFrOWPuOi1hOaWmQ==
全球首个FGFR4抑制剂联合IO在HCC的临床设计:依帕戈替尼联合阿替利珠单抗的临床二期试验方案_第5页
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
所属报告: 和誉(2256.HK)-港股公司首次覆盖:中国小分子新药研发标兵迎接商业化转型元年-251002(44页).pdf
打包全文图表

相关数据

客服
商务合作
小程序
服务号
折叠